4.8 Article

Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

期刊

NATURE COMMUNICATIONS
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-03473-9

关键词

-

资金

  1. NIH [R01EB022563, R01CA210273]
  2. MTRAC for Life Sciences Hub
  3. UM Forbes Institute for Cancer Discovery Pilot Grant
  4. Emerald Foundation
  5. Melanoma Research Alliance [348774]
  6. DoD/CDMRP Peer Reviewed Cancer Research Program [W81XWH-16-1-0369]
  7. NSF CAREER Award [1553831]
  8. UM Rackham and AFPE
  9. Broomfield International Student Fellowship
  10. AHA Predoctoral Fellowship [15PRE25090050]
  11. NIH Tetramer Core Facility [HHSN272201300006C]
  12. Div Of Chem, Bioeng, Env, & Transp Sys
  13. Directorate For Engineering [1553831] Funding Source: National Science Foundation

向作者/读者索取更多资源

Photothermal therapy (PTT) is a promising cancer treatment modality, but PTT generally requires direct access to the source of light irradiation, thus precluding its utility against disseminated, metastatic tumors. Here, we demonstrate that PTT combined with chemotherapy can trigger potent anti-tumor immunity against disseminated tumors. Specifically, we have developed polydopamine-coated spiky gold nanoparticles as a new photothermal agent with extensive photothermal stability and efficiency. Strikingly, a single round of PTT combined with a sub-therapeutic dose of doxorubicin can elicit robust anti-tumor immune responses and eliminate local as well as untreated, distant tumors in >85% of animals bearing CT26 colon carcinoma. We also demonstrate their therapeutic efficacy against TC-1 submucosa-lung metastasis, a highly aggressive model for advanced head and neck squamous cell carcinoma (HNSCC). Our study sheds new light on a previously unrecognized, immunological facet of chemo-photothermal therapy and may lead to new therapeutic strategies against advanced cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据